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ABSTRACT    
The number of individuals with diabetes is increasing worldwide and a large subset of those affected will 
develop diabetic nephropathy.  Diabetic nephropathy is the leading cause of end-stage renal disease, has 
serious health consequences for affected individuals, and represents a major monetary cost to healthcare 
providers.   
Technological and analytical developments have enabled large-scale, collaborative studies that are revealing 
risk factors associated with diabetic nephropathy.  However, much of the inherited predisposition and 
biological mechanisms underpinning risk of this disease remain to be identified.  Meta-analyses and 
integrated pathway studies are becoming an increasingly important part of research for diabetic 
nephropathy including, genetic, epigenetic, transcriptomic, proteomic research, clinical observations and the 
development of animal models.   
This report highlights current bioinformatic resources and standards of reporting to maximise 
interdisciplinary research for diabetic nephropathy.  The identification of an -Omics profile that can lead to 
earlier diagnosis and / or offer improved clinical evaluation of individuals with diabetes would not only 
provide significant health benefits to affected individuals, but may also have major utility for the efficient 
use of healthcare resources.   
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Introduction: Diabetes is a major public health 
concern with rates of diabetes increasing globally and 
approximately 40% of affected individuals developing 
diabetic nephropathy 1,2,3,.  Diabetic nephropathy is the 
leading cause of end-stage renal disease and represents 
a substantial cost to healthcare providers 5,.  Strategies 
that can help predict those individuals at higher risk of 
developing diabetic nephropathy, improve understanding 
of the pathogenesis of this disease, or suggest novel 
targets for optimised therapies are urgently required.  
With the increasing size and complexity of research 
studies, bioinformatics has become an essential 
discipline to help unravel the biological mechanisms that 
lead to diabetic nephropathy and end-stage renal 
disease in individuals with diabetes.  Clinically-based 
resources such as routine laboratory measurements, 
hospitalisation records, treatment regimens and patient 
outcomes may help inform strategic planning, change 
healthcare policy, and contribute to „basic‟ research 
discoveries 7,.  Epidemiological studies confirm inherited 
risk factors influence the development and progression 
of diabetic nephropathy, however identifying clinically 
useful biomarkers and effective therapies is proving to 
be considerably more challenging.  Recent technological 
advances enable cost-effective investigations of 
functional risk factors for diabetic nephropathy including 
genetic, epigenetic, transcriptomic, proteomic and 
metabolomic pathways coupled with data from clinical 
observations and animal models of diabetic kidney 
disease.  Analysing integrated networks and pathways 
from rich and diverse data sources, often using systems 
biology-based approaches, is becoming an important 
component of diabetic nephropathy research.    
 
Genetic Studies:  Genetic epidemiology is 
moving away from single SNP studies, towards an 
emphasis on the comprehensive analysis of a candidate 
gene 9,1 or systematic literature reviews and meta-
analyses 11,12,13,14,1.  Several genome-wide association 
studies (GWAS) have been performed for diabetic 
nephropathy 16,17,18,19,20,2, but only two independent 
GWAS datasets are publicly available via dbGaP: (i) 
GoKinD US 1 and (ii) All Ireland-Warren3-GoKinD UK 2 
collections.  Recently, the GENIE consortium completed 
the first meta-analysis of GWAS for diabetic nephropathy 
with subsequent replication in more than 12,500 
individuals 2.  Ongoing projects involve more 
comprehensive association studies in larger discovery 
cohorts together with deep next-generation 
resequencing to identify more elusive rare variants that 
may contribute to diabetic nephropathy.  These types of 
studies maximise the chance of finding true genetic 
signals that influence risk of diabetic kidney disease, or 
the more extreme end-stage renal disease in individuals, 
but pose substantial challenges in terms of archiving the 
data so that it is usefully accessible to other researchers.  
„Raw‟ datasets that are available to bona fide 
researchers are ideal in that they facilitate downstream 
analyses by whichever methods are most appropriate for 
individual applications (Table 1).  Several older 
resources such as T2D-db 2 (http://t2ddb.ibab.ac.i, last 
updated for type 2 diabetes in 2009) and CORGI 2 
(http://go.qub.ac.uk/Kidney-CORG, last updated for 
kidney genes in 2011) also contain useful data that 
support and promote interdisciplinary research. 
 
Comprehensive clinical and demographic information is 
very important when researchers combine data from 
multiple studies 2. Knowing the precise phenotype, 
inclusion/exclusion criteria, and potential confounding 
factors such as duration of diabetes and ancestry are 
critical to derive robust findings from meta-analyses.  
Quality control is another essential element of all genetic 
studies, particularly in larger-scale studies where 
systematic bias may substantially affect the results; 
stringent quality control was highlighted as very 
important for a diabetic nephropathy GWAS study 2.  
Standardised guidelines have been suggested to help 
evaluate published genetic association studies and 
improve transparency of reporting; STrengthening the 
REporting of Genetic Association Studies (STREGA): an 
extension of the STROBE statement 2. 
 
Gene Expression Studies:  Multiple 
studies have been reported that suggest transcriptomic 
differences between individuals with and without 
diabetic nephropathy.  Traditionally larger-scale studies 
of the transcriptome were conducted using DNA 
microarrays that comply with reporting standards 
designed to improve reliability and confidence in 
outcomes such as MIAME 2 and MAQC 2.  Several 
transcriptomic studies are publicly available in the Gene 
Expression Omnibus 2, Nephromine 3, GUDMAP 3, and 
KUPKB 3.  RNA-seq is a powerful sequence-based 
method that enables researchers to discover RNA 
biomarkers, novel isoforms, and to profile and quantify 
entire RNA transcripts across the transcriptome. RNA-
seq may also provide insights into the potential 
functional impact of epigenetic modification to DNA and 
histones 33,3.  RNA-Seq will provide more reliable, precise 
and informative measurements of the transcriptome, 
however challenges remain in terms of the sheer 
quantity of data generated and researcher‟s unfamiliarity 
with this rapidly developing technique.  Nonetheless, 
RNA-Seq is generating novel insights for the kidney 
transcriptome that are relevant for diabetic nephropathy 
3. 
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Epigenetic Studies:   
Epigenetic modifications of the genome contribute to 
disease susceptibility, however much of the “inherited” 
epigenetic architecture remains unexplained. Emerging 
evidence for epigenetic phenomena has transformed 
investigations of heritable influences on disease and, 
complementary to genome-wide association studies 
(GWAS), it is now cost-effective to perform population-
based studies of the epigenome 36,3. Epigenetic 
modifications modulate gene expression without 
changing the DNA sequence; these may be either stably 
inherited or dynamic epigenetic marks.  Methylation is a 
key epigenetic feature that plays an important role in 
chromosomal integrity and regulation of gene expression 
with different methylation profiles now being associated 
with many complex diseases, including diabetes 38,3.  
Initial studies support an important role for differential 
methylation in diabetic nephropathy 40,4, however as yet 
only one dataset is publicly available via the Gene 
Expression Omnibus 2.  It is feasible that methylation 
profiles may lead to clinically useful biomarkers or direct 
researchers to novel therapeutic targets in individuals 
with diabetes.  The identification of a genetic-epigenetic 
profile that can lead to earlier diagnosis and / or offer 
improved clinical evaluation would not only provide 
significant healthcare benefits to affected individuals, 
but may also have major utility for the efficient use of 
monetary resources 
 
Other epigenetic features include chromatin regulation 
and RNA interference.  Histone modifications do play a 
role in diabetic nephropathy 4, but large scale studies 
are not yet available.  MicroRNAs have been an area of 
intense interest in recent years, with several markers 
highlighted with functionally important to modulate 
diabetic nephropathy 43,44,4.  Non-protein coding RNAs 
are attractive targets for therapeutic intervention and as 
clinically useful biomarkers in the development of 
diabetic nephropathy.  It is possible that epigenetic 
regulation of gene expression may represent a major 
contribution for diabetic nephropathy An epigenomics 
resource at the National Center for Biotechnology 
Information (NCBI) has been created to serve as a 
comprehensive public repository for whole-genome 
epigenetic data sets 4. 
 
Proteome Studies: Diabetic nephropathy 
involves a complex interaction of biological processes 
and proteomic analysis represents a potentially powerful 
approach to identify clinically relevant biomarkers.  
Centralised repositories exist for proteomic data such as 
the PRIDE (PRoteomics IDEntifications database; 
www.ebi.ac.uk/prid), and the Human Metabolome 
Database 4 has been developed for metabolomic data, 
but broadly accepted experimental and reporting 
standards for large-scale studies are still under 
development 48,49,5.  Promising biomarkers for diabetic 
nephropathy are being suggested from multicentre 
collaborations and the integration of experimental and 
clinical data 51,5.   
 
An Integrated Approach:   
Efficient bioinformatic tools are becoming increasingly 
important to maximise the outcomes from individual and 
collaborative multi-centre research programmes.  Web-
based resources that store, organise and present 
complex information from diverse datasets enhance 
effective research.  Once such example that facilitates 
access to multidisciplinary information is dkCOIN 5; this 
collaborative resource was recently launched to share 
information from the  Beta Cell Biology Consortium, the 
Nuclear Receptor Signalling Atlas, the Diabetic 
Complications Consortium, and Mouse Metabolic 
Phenotyping Centres.  A systematic, multidisciplinary 
approach that combines clinical insight with basic 
biological research is not yet publicly available for 
diabetic nephropathy, but the use of integrated datasets 
is increasing (Figure 1).  SysKid (systems biology 
towards novel chronic kidney disease diagnosis and 
treatment) is a consortium-driven effort that aims to 
define a comprehensive picture of the consequences of 
diabetes on kidney function (www.syskid.e), although 
data is not publicly available.  Systems biology is 
providing novel insights for diabetes 54,55,5 and for 
diabetic nephropathy in particular 57,58,5.   
 
With the development of population based registries and 
biobank information, it is possible that clinical and 
research oriented databases will be integrated to form a 
rich, linked information resource, however multiple 
ethical and legal challenges need to be overcome before 
this becomes practical 60,61,62,6.  The identification of an -
Omics profile that can lead to earlier diagnosis and / or 
offer improved clinical evaluation would not only provide 
significant health benefits to affected individuals, but 
may also have major utility for the efficient use of 
healthcare resources.  Bioinformatics is a key discipline 
that can aid our understanding of the initiation and 
progression of diabetic nephropathy. In addition, 
relevant education of healthcare providers is also 
important to ensure clinically relevant outcomes from –
Omics projects that will help patient evaluation and 
management. 
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Resource Description Link 
GUDMAP 
GenitoUrinary Development Molecular Anatomy 
Project 
Curated, gene expression datasets in development transgenic 
mice 
www.gudmap.org 
KUPKB 
The Kidney and Urinary Pathway Knowledge Base 
-Omics datasets from scientific publications and other renal 
databases 
http://www.kupkb.org 
Nephromine Comprises renal gene expression profiles www.nephromine.org 
T1DBASE 
Type 1 Diabetes Database 
Curated, integrated datasets informing genetics across species www.t1dbase.org 
DiaComp 
Diabetic complications consortium 
Data on animal models for diabetic complications, including 
nephropathy. 
www.diacomp.org 
dkCOIN 
National Institute of Diabetes, Digestive and Kidney 
Diseases  (NIDDK) Consortium Interconnectivity 
Network 
Toolkit of interconnected resources (datasets, reagents, and 
protocols) 
generated from individual consortia 
www.dkcoin.org 
dbGAP:  Genotype-phenotype association studies 
 
phs000088.v1.p1 
phs000018.v1.p1 
Susceptibility Genes for Diabetic Nephropathy in 
Type 1 Diabetes (GoKinD study participants and 
parents), NIDDK 
  
phs000302.v1.p1 
Genetic Study on Nephropathy in Type-2 Diabetes 
  
phs000333.v1.p1 
Family Investigation of Nephropathy and Diabetes 
(FIND) Study 
  
phs000389.v1.p1 
GENIE UK-ROI Diabetic Nephropathy GWAS 
  
  
  
  
Case-control study for nephropathy in type 1 diabetes with 1825 
participants using Affymetrix 500K set 
  
CC study for nephropathy in type 2 diabetes with 350 participants 
using Illumina 370CNV array. 
  
CC study for nephropathy in type 2 diabetes with 2622 partici-
pants using Affymetrix 6.0 
  
  
Case-control study for nephropathy in type 1 diabetes with 1801 
participants using Illumina Omni1-quad 
http://www.ncbi.nlm.nih.gov/projects/gap 
GEO: Gene expression omnibus 
  
GSE20067 
  
GSE1009 
  
  
GDS3649 
  
  
GDS961 
  
  
Case-control approach on 192 individuals using Illumina’s Infini-
um 27k methylation beadchip 
  
Expression profiling on 6 kidney samples using Affymetrix 
Human Genome U95 Version 2 
  
Analysis of HK2 proximal tubular cells using Illumina Hu-
manWG-6 v3.0 expression beadchip 
  
Case-control comparison of glomeruli 
http://www.ncbi.nlm.nih.gov/geo/ 
Table 1: Web-based resources 
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Figure 1:  An integrated approach for diabetic nephropathy  
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